Atrial fibrillation, the most common arrhythmia, currently affects more than 10 million people in Europe, with a projection of 14-17 million by 2030.
It is characterized by irregular and rapid heartbeats. Very disabling, its impact on the quality of life of those affected is as great as that of coronary artery disease (myocardial infarction). It is the most common cause of cardioembolic stroke and a risk factor for heart failure and dementia.
Understanding atrial fibrillation
Atrial fibrillation manifests itself by an uncontrolled electrical activation and thus an ineffective contraction of the atrium, which promotes the formation of blood clots. The heartbeat becomes rapid and irregular.
Treating atrial fibrillation
Several years ago, Liryc doctors identified the triggers of atrial fibrillation in the pulmonary veins. This discovery led to the development of a non-pharmaceutical treatment of this disease.
This treatment consists of cauterizing the pulmonary veins by a radiofrequency catheter so as to exclude these arrhythmia triggers. This approach has become the treatment of reference: to date, over 300,000 patients undergo it each year worldwide.